Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A compassionate access program assessing the combination of Veyonda with 177Lu-PSMA therapy for patients with advanced, treatment resistant, metastatic prostate cancer (mCRPC) being treated with theranostics

Next Previous
X
Search
Trial Profile

A compassionate access program assessing the combination of Veyonda with 177Lu-PSMA therapy for patients with advanced, treatment resistant, metastatic prostate cancer (mCRPC) being treated with theranostics

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
  • Indications Prostate cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Noxopharm

    • Most Recent Events

    • 30 Jun 2022 Status changed from suspended to planning, According to a Novartis media release.
    • 30 Jun 2022 According to Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
    • 05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top